ImmunogenX, Inc. is a clinical-stage company founded in 2013 and supported by a team of world renowned scientists and collaborators. ImmunogenX was formed to address critical needs for individuals with suspected or diagnosed celiac disease. ImmunogenX is currently conducting two Phase 2b clinical research trials and has completed one study on latiglutenase, an investigational medication designed to relieve common symptoms suffered by those with celiac disease.